Clasado, the manufacturers and suppliers of Bimuno®, a unique trans-galactooligosaccharide prebiotic, have announced the results of a clinical study on the use of the Bimuno (B-GOS) to alter bacteria in the human gastrointestinal tract as a candidate to help prevent and manage Metabolic Syndrome. The results from the study will be published in the March 2013 issue of The Journal of Nutrition. The double-blind, randomized, placebo-controlled, crossover study has been conducted on behalf of Clasado by a research team led by Dr...
More...
More...